Omeprazole Pinewood Laboratories (Omeprazole)

Omeprazole acts on the gastric proton pump to manage acid‑related disorders.

• Gastro‑esophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis.
• Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion.
• NSAID‑associated gastropathy: lowers incidence of ulcer formation.
• Helicobacter pylori eradication regimens: enhances effectiveness of antibiotic therapy.

• Omeprazole selectively inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located in the parietal cells of the stomach lining. By forming a covalent bond with the pump’s cysteine residues, it blocks the final step of acid secretion, leading to a sustained increase in gastric pH and reduced acidity throughout the dosing interval.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild and transient.
• Diarrhea: usually self‑limiting.
• Nausea: occasional mild discomfort.
• Abdominal pain: mild cramping.
• Flatulence: increased gas.
• Constipation: occasional bowel change.

Serious or Rare Side Effects

• Clostridioides difficile infection: severe colitis risk.
• Acute interstitial nephritis: kidney inflammation.
• Hypomagnesemia: low magnesium levels.
• Osteoporotic fractures: increased risk with long‑term use.
• Stevens‑Johnson syndrome: rare severe skin reaction.
• Liver enzyme elevation: potential hepatic impact.

When prescribing Omeprazole, consider the following safety measures:

• Assess renal function: adjust use in severe impairment.
• Review hepatic status: use cautiously in liver disease.
• Evaluate long‑term need: limit duration to the shortest effective period.
• Monitor electrolytes: watch for magnesium depletion with prolonged therapy.
• Counsel on infection risk: inform patients about possible C. difficile symptoms.
• Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omeprazole may affect the plasma concentration of several co‑administered medicines.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk.
• Atazanavir: decreased antiviral absorption, risking treatment failure.
• Dasatinib: lowered exposure, potentially reducing efficacy.

Moderate Interactions (Monitor Closely)

• Warfarin: enhanced anticoagulant effect, requiring INR monitoring.
• Phenytoin: increased metabolism, possibly lowering seizure control.
• Methotrexate: reduced clearance, risk of toxicity.
• Ketoconazole: decreased absorption, may need dose adjustment.